ADC Therapeutics (ADCT) Fundamental Analysis: Revenue, Earnings & Valuation

5.66 / 10

Netural

ADC Therapeutics shows a moderate fundamental profile with an Interest coverage ratio of 15.5 and Total operating revenue growth of 8.1%, but a low Net profit / Total profit ratio of 101.0. These factors balance out, resulting in a neutral fundamental rating and only moderate investment consideration.

Analysis Checks(9/10)

Revenue-MV

Value-1.36

Score2/3

Weight20.72%

1M Return10.54%

Total operating revenue (YoY growth rate %)

Value8.11

Score3/3

Weight1.34%

1M Return0.88%

Inventory turnover ratio

Value0.23

Score3/3

Weight-1.63%

1M Return-1.05%

Profit-MV

Value0.47

Score2/3

Weight16.74%

1M Return8.99%

PB-ROE

Value0.33

Score3/3

Weight24.09%

1M Return13.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.51

Score2/3

Weight-1.81%

1M Return-1.25%

Operating revenue (YoY growth rate %)

Value8.11

Score2/3

Weight0.15%

1M Return0.10%

Asset-MV

Value-0.51

Score3/3

Weight26.56%

1M Return11.94%

Net profit / Total profit (%)

Value101.05

Score1/3

Weight-2.24%

1M Return-1.59%

Cash-MV

Value-0.07

Score2/3

Weight16.07%

1M Return8.80%

Is ADCT undervalued or overvalued?

ADCT scores 5.66/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -221.97% net margin, -2.65 P/E ratio, -1.89 P/B ratio, and 41.00% earnings growth, these metrics solidify its Netural investment rating.